Loading…
Biodexa Pharmaceuticals Plc is projected to rise to $1.63 by 2027, a +15% move from its current price of $1.42. BDRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.35 | $1.42 | $1.49 | +0.08% |
| Aug 6 | $1.33 | $1.42 | $1.52 | +0.15% |
| Aug 7 | $1.31 | $1.42 | $1.55 | +0.23% |
| Aug 8 | $1.29 | $1.42 | $1.57 | +0.30% |
| Aug 9 | $1.28 | $1.43 | $1.59 | +0.38% |
| Aug 10 | $1.27 | $1.43 | $1.61 | +0.45% |
| Aug 11 | $1.26 | $1.43 | $1.62 | +0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.26 | $1.43 | $1.62 | +0.53% |
| Week 2 | $1.20 | $1.43 | $1.72 | +1.06% |
| Week 3 | $1.16 | $1.44 | $1.80 | +1.59% |
| Week 4 | $1.12 | $1.45 | $1.87 | +2.12% |
| Week 5 | $1.09 | $1.46 | $1.94 | +2.66% |
| Week 6 | $1.07 | $1.47 | $2.01 | +3.20% |
| Week 7 | $1.05 | $1.47 | $2.07 | +3.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biodexa Pharmaceuticals Plc is a clinical stage biopharmaceutical company focused on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
The company also develops MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior.
The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
BDRX is Biodexa Pharmaceuticals Plc, a micro-cap healthcare company trading at $1.32 per share with a market cap of $1.19M and ranking 5484 by market capitalization. The stock is characterized by a neutral near-term technical stance but broad multi-year forecasting that projects upside potential later in the decade.
Current price and market position are modest, reflecting its small market capitalization. The current price is $1.32 and the market cap is $1.19M, with a rank of 5484. The forecast suggests a range of outcomes across years, with near-term stability and longer-term upside potential, including higher max prices in the 2030s to 2050.
The forecast highlights several years with positive ROIs and a shift toward bullish sentiment in the mid-2030s and beyond, though it also records a bearier period around 2031.
A major floor 88.7% below — a decisive break under it would weaken the trend.
The nearest floor, 7.0% below — buyers have tended to step in here.
The nearest ceiling, 115.5% above — a clean break opens room to run.
A major ceiling 242.3% above — clearing it would confirm fresh momentum.
Key BDRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.45 | Sell | $1.46 | Sell |
| MA 10 | $1.62 | Sell | $1.63 | Sell |
| MA 20 | $2.03 | Sell | $1.94 | Sell |
| MA 50 | $2.67 | Sell | $2.61 | Sell |
| MA 100 | $3.15 | Sell | $4.94 | Sell |
| MA 200 | $10.77 | Sell | $207.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 16.98 | Buy |
| Stoch RSI (14) | 2.23 | Buy |
| CCI (20) | -112.96 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -41.07 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.91 | Sell |
| Awesome (5,34) | -0.93 | Sell |
| Ultimate (7,14,28) | 8.93 | Buy |
| Momentum (10) | -0.81 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 1.35 | Buy |
| ADX (14) | 44.16 | Sell |
| ATR (14) | 0.09 | Info |
30-day technical picture is neutral. RSI14 is 20, indicating room for downside pressure, while the short-term trend is reflected in a SMA50 of $2.67 and SMA200 at $10.77. The stock sits near a support level of $1.32 and faces a resistance near $3.06.
Over the last 30 days the price traded in a range from a low of $0.9595 to a high of $1.82, illustrating limited upside momentum in the immediate term while still remaining above the pivotal support at $1.32.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.32 | $1.42 | $1.84 | 0% | Neutral | |
| $1.21 | $1.63 | $2.36 | +15% | Neutral | |
| $1.02 | $1.45 | $2.24 | +2% | Neutral | |
| $0.9376 | $1.40 | $2.26 | -2% | Neutral | |
| $0.889 | $1.38 | $2.32 | -3% | Neutral | |
| $0.7306 | $1.18 | $2.05 | -17% | Bearish | |
| $0.9378 | $1.57 | $2.80 | +11% | Neutral | |
| $1.14 | $1.98 | $3.63 | +40% | Bullish | |
| $1.06 | $1.91 | $3.58 | +34% | Bullish | |
| $0.9778 | $1.81 | $3.48 | +28% | Bullish | |
| $1.24 | $2.70 | $5.66 | +90% | Bullish | |
| $1.37 | $3.05 | $7.00 | +114% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.32 | $1.42 | $1.71 | +0.00% |
| September 2026 | $1.19 | $1.44 | $1.82 | +1.69% |
| October 2026 | $1.24 | $1.52 | $1.95 | +5.30% |
| November 2026 | $1.19 | $1.47 | $1.91 | -3.50% |
| December 2026 | $1.12 | $1.40 | $1.84 | -4.67% |
Click any year to see its month-by-month BDRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BDRX price prediction for 2026 points to an average of $1.42 (low $1.32, high $1.84) — a potential gain of 0% on today's $1.42. A consolidation phase looks the most probable path here.
In 2027, BDRX is projected to trade between $1.21 and $2.36, averaging $1.63 — a potential gain of +15% from today's $1.42. That is up +15% on the projected 2026 average. Price action looks broadly range-bound.
Biodexa Pharmaceuticals Plc's 2028 outlook centres on $1.45, within a $1.02 to $2.24 range. That is -11% versus the projected 2027 average. That marks a +2% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, BDRX could reach as high as $2.26, with a base case around $1.40 and support toward $0.9376 — roughly -2% from $1.42. Price action looks broadly range-bound.
Expect BDRX to range from $0.889 to $2.32 through 2030. The $1.38 average target implies a -3% move from current prices. That is -1% versus the projected 2029 average. A consolidation phase looks the most probable path here.
The BDRX price prediction for 2031 points to an average of $1.18 (low $0.7306, high $2.05) — a potential decline of -17% on today's $1.42. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2032, BDRX is projected to trade between $0.9378 and $2.80, averaging $1.57 — a potential gain of +11% from today's $1.42. That is up +33% on the projected 2031 average. A consolidation phase looks the most probable path here.
Biodexa Pharmaceuticals Plc's 2033 outlook centres on $1.98, within a $1.14 to $3.63 range. That is up +26% on the projected 2032 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2034, BDRX could reach as high as $3.58, with a base case around $1.91 and support toward $1.06 — roughly +34% from $1.42. Buyers look set to stay in control over this stretch.
Expect BDRX to range from $0.9778 to $3.48 through 2035. The $1.81 average target implies a +28% move from current prices. That is -5% versus the projected 2034 average. Momentum favours further upside here.
The BDRX price prediction for 2040 points to an average of $2.70 (low $1.24, high $5.66) — a potential gain of +90% on today's $1.42. Buyers look set to stay in control over this stretch.
In 2050, BDRX is projected to trade between $1.37 and $7.00, averaging $3.05 — a potential gain of +114% from today's $1.42. That is up +13% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BDRX today (≈ 704.225352 BDRX) could be worth
$2,144.51
+$1,144.51 (+114%) by 2050 · US Dollar
Based on the average projected BDRX price of $3.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDRXwould be worth at today's price.
$1,000 invested in BDRX on Jul 31, 2025 (≈ 25.477707 BDRX) would be worth
$36.18
-$963.82 (-96.4%) today · 0.04× · US Dollar
Based on a BDRX entry price of $39.25 vs. today's $1.42.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.65 | $860.61 | -13.9% |
| 1 month ago | $3 | $473.33 | -52.7% |
| 3 months ago | $3.03 | $468.65 | -53.1% |
| 6 months ago | $8.5 | $167.06 | -83.3% |
| 1 year ago | $39.25 | $36.18 | -96.4% |
| All time (5.0y) ago | $3,780,000 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDRX forecast.
Our base-case forecast reaches $2.80 around 2050.
Implied market cap at $2.80: $2.53M
The multi-year forecast covers 2026 through 2050, with the average price expectations showing a gradual uptick after a subdued 2026 and a notable improvement from the mid-2030s onward. In 2030 the forecast average is $1.29 with a max of $2.16 and a min of $0.8271, delivering a -2.6% ROI and a neutral sentiment. The outlook for 2031 shows a bearish tone with an average of $1.09 and a -17.1% ROI.
In the 2033–2035 window the averages rise to $1.85, $1.77, and $1.69 with ROIs of 40%, 34.1%, and 27.8% respectively, accompanied by bullish sentiment. The forecast continues to deteriorate/slightly improve in 2032 (neutral, average $1.46) before shifting to bullish in 2033 and remaining so through 2050, where the averages reach $2.51 by 2040 and $2.83 by 2050 with ROIs of 90.1% and 114.4% respectively.
Overall, the path shows a move from neutral to bullish sentiment after 2032, with sizable upside potential in the 2040s and 2050s, though intermediate years exhibit risk and volatility, including a defined bearish phase in 2031.
Tap a question to reveal the answer.
2030 avg price $1.29, min $0.8271, max $2.16, ROI -2.6%, sentiment NEUTRAL.
The forecast shows mixed signals: a neutral outlook near-term with a bear in 2031 and bullish momentum emerging in 2033 onward; ROIs vary from negative in early years to positive, reaching 90.1% in 2040 and 114.4% in 2050, so outcomes are uncertain and not guaranteed.
Yes, the max forecast values include $3.39 in 2033 and $3.32 in 2034, indicating potential to reach around $3 in the mid-2030s according to the provided projections.
Current price is $1.32 and market cap is $1.19M.
The highest ROI is projected for 2050 at 114.4%, with a strong bullish sentiment.
Biodexa Pharmaceuticals Plc Community Discussion
0Share your Biodexa Pharmaceuticals Plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.